Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled t
about
Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical reviewMetabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads.Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
P2860
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled t
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@en
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@nl
type
label
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@en
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@nl
prefLabel
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@en
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@nl
P2093
P2860
P356
P1433
P1476
Eicosapentaenoic acid could pe ...... ective randomized controlled t
@en
P2093
Hiroiku Kawakami
Hiroshi Aikata
Hiroto Ishihara
Kazuaki Chayama
Keiji Tsuji
Kenichi Satoh
Michio Imamura
Mikiya Kitamoto
Shintaro Takaki
Shiomi Aimitsu
P2860
P304
P356
10.1159/000114718
P577
2007-01-01T00:00:00Z